Infiltration by dendritic cells (DCs) is a common feature of most human tumors. Prior studies evaluating the interaction of DCs with tumors have focused largely on their immunologic properties (for review see Banchereau, J., and R.M. Steinman. 1998. Nature. 392:245–252). In this study, we show that the clonogenicity of several human tumor cell lines and primary tumor cells from myeloma patients is enhanced by their interactions with DCs. Myeloma cells cultured in the presence of DCs have an altered phenotype with an increased proportion of cells lacking terminal plasma cell differentiation marker CD138. DC–tumor interaction also leads to the up-regulation of B cell lymphoma 6 expression in myeloma cells. Effects of DCs on myeloma cells are inhibited by blockade of the receptor activator of NF-kB (RANK)–RANK ligand and B cell–activating factor–APRIL (a proliferation-inducing ligand)-mediated interactions. Together, these data suggest that tumor–DC interactions may directly impact the biology of human tumors, particularly multiple myeloma, and may be a target for therapeutic intervention.
Skip Nav Destination
Article navigation
7 August 2006
Brief Definitive Report|
July 31 2006
Enhancement of clonogenicity of human multiple myeloma by dendritic cells
Anjli Kukreja,
Anjli Kukreja
1Laboratory of Tumor Immunology and Immunotherapy
Search for other works by this author on:
Aisha Hutchinson,
Aisha Hutchinson
1Laboratory of Tumor Immunology and Immunotherapy
Search for other works by this author on:
Kavita Dhodapkar,
Kavita Dhodapkar
2Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, NY 10021
Search for other works by this author on:
Amitabha Mazumder,
Amitabha Mazumder
3St. Vincent's Cancer Center, New York, NY 10021
Search for other works by this author on:
David Vesole,
David Vesole
3St. Vincent's Cancer Center, New York, NY 10021
Search for other works by this author on:
Revathi Angitapalli,
Revathi Angitapalli
1Laboratory of Tumor Immunology and Immunotherapy
Search for other works by this author on:
Sundar Jagannath,
Sundar Jagannath
3St. Vincent's Cancer Center, New York, NY 10021
Search for other works by this author on:
Madhav V. Dhodapkar
Madhav V. Dhodapkar
1Laboratory of Tumor Immunology and Immunotherapy
4Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021
Search for other works by this author on:
Anjli Kukreja
1Laboratory of Tumor Immunology and Immunotherapy
Aisha Hutchinson
1Laboratory of Tumor Immunology and Immunotherapy
Kavita Dhodapkar
2Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, NY 10021
Amitabha Mazumder
3St. Vincent's Cancer Center, New York, NY 10021
David Vesole
3St. Vincent's Cancer Center, New York, NY 10021
Revathi Angitapalli
1Laboratory of Tumor Immunology and Immunotherapy
Sundar Jagannath
3St. Vincent's Cancer Center, New York, NY 10021
Madhav V. Dhodapkar
1Laboratory of Tumor Immunology and Immunotherapy
4Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021
CORRESPONDENCE Madhav V. Dhodapkar: [email protected]
Received:
October 21 2005
Accepted:
June 29 2006
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2006
J Exp Med (2006) 203 (8): 1859–1865.
Article history
Received:
October 21 2005
Accepted:
June 29 2006
Citation
Anjli Kukreja, Aisha Hutchinson, Kavita Dhodapkar, Amitabha Mazumder, David Vesole, Revathi Angitapalli, Sundar Jagannath, Madhav V. Dhodapkar; Enhancement of clonogenicity of human multiple myeloma by dendritic cells . J Exp Med 7 August 2006; 203 (8): 1859–1865. doi: https://doi.org/10.1084/jem.20052136
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement